IndieBio

IndieBio Research Investment Thesis IndieBio is the world's first startup accelerator exclusively focused on synthetic biology and life sciences, operating as a program of SOSV, a global venture capital firm with $1.5 billion in assets under management. The fund was founded on the belief that the most impactful innovations will come from using biology as an engineering tool to solve humanity's greatest challenges in health, food, climate, and materials. IndieBio pioneers deep tech biotech investments at the earliest stages, providing not just capital but also wet lab infrastructure, mentorship, and investor networks. The firm explicitly targets founders who are "too early" for traditional biotech investors—scientists and engineers with breakthrough ideas but minimal proof of concept. Investment Philosophy and Approach IndieBio operates with a founder-centric philosophy that goes beyond typical accelerator dynamics: High-touch mentorship : Founders get personal 1:1 relationships with 5 partners simultaneously, with daily interaction possible (not quarterly check-ins) Wet lab infrastructure : Companies co-locate in BSL-rated wet labs owned by the fund, providing bio-hazard facilities at no additional cost Long-term capital partnership : 97% participation rate in follow-on rounds >$1M, continuing to invest through Series C Diversity as core thesis : 42% female founder rate, first-time founders welcomed, 40+ nationalities represented No curriculum mentality : Personalized support rather than cohort-based "box-checking" Stage Focus and Check Sizes IndieBio makes pre-seed and seed investments: Initial Investment : Up to $525,000 per company (one of the largest pre-seed checks in the market) Follow-on Pattern : 97% participation rate in seed/Series A+ rounds exceeding $1 million Capital Deployment : 80% of SOSV's capital is deployed post-program, demonstrating long-term commitment Fund Reserves : Approximately 75% of funds are reserved for follow-on investments through SOSV integration Sector and Thesis Focus IndieBio companies span the entire spectrum of synthetic biology and life sciences applications: Primary Focus Areas : Therapeutics & Biotech : Cell and gene therapies, drug discovery platforms, molecular medicines Climate Tech : Sustainable materials, carbon-conserving microbes, alternative proteins Agtech : Climate-resilient crops, soil health, alternative proteins, fermentation-based foods Materials : Bio-based alternatives to leather, textiles, chemicals using engineered organisms Food Innovation : Cultured meat, fermented proteins, alternative seafood, molecular flavoring Diagnostics : Physical AI for disease detection, biomarker identification Industrial Biotech : Sustainable manufacturing, enzyme engineering, circular economy solutions Notable Portfolio Coverage : 270+ companies funded across 40+ countries $12B+ in enterprise value created Current portfolio includes 3 unicorns (NotCo, Prellis Biologics, MycoWorks) 7 portfolio exits to date Recent Activity and Fund Status IndieBio is actively deploying from SOSV Fund V ($306M, announced April 2025), the firm's largest fund yet: Recent Investments (2025-2026) : December 2025: FluoSphera (Drug Discovery) November 2025: Hoofprint Biome (portfolio alum secured $15M Series A) October 2025: Helex Therapeutics (raised $3.5M seed for non-viral gene therapies) Continuous seed-stage investments across climate, food, and therapeutics Fund Status : ACTIVELY DEPLOYING from Fund V with target of 60 pre-seed and 150 follow-on investments annually Portfolio Activity : Portfolio companies raised $1B+ in fresh capital in 2024-2025, including 80+ seed rounds and 40+ later-stage financings Geographic Reach IndieBio operates two primary locations: San Francisco : Original location, SF Cohort 16 (2025) in progress New York : Expanded presence, NY Cohort 9 (2024), $25,000 sq ft office/lab at 7 Penn Plaza (opened 2025) Remote capability : Companies can operate anywhere globally with occasional in-person visits Team and Leadership IndieBio Leadership : Po Bronson (Managing Director, SOSV & General Partner): Science journalist (9 national awards, 7 bestselling books), author of "Decoding the World," background in Economics and Arthur Andersen consulting Pae Wu (General Partner, SOSV & CTO): Former Scientific Director at Telefónica's Alpha moonshot factory, Science Director at US Office of Naval Research-Global, DARPA technical consultant, PhD in Electrical Engineering (Duke), BSE (Princeton) Mohan S. Iyer (General Partner, SOSV & IndieBio): Deep tech investor with biotech expertise Deborah Zajac (General Partner, SOSV & IndieBio): Newest GP hire (2025), focused on NY operations Parikshit Sharma (Partner): Core investment team member Alex Kopelyan (Senior Director & Partner): Portfolio support and technical oversight Westley Dang (CSO & Partner): Chief Scientific Officer guiding portfolio companies Sean O'Sullivan (Managing General Partner, SOSV): Serial founder, entrepreneur, philanthropist, founder of SOSV Parent Fund Context: SOSV IndieBio is one program within SOSV, a broader deep tech vehicle: Founding Year : 2001 Assets Under Management : $1.5 billion Portfolio Scale : 800+ total companies across all SOSV programs Programs : IndieBio (biotech), HAX (hardware), and other deep tech verticals Investment Philosophy : "The First Check in Deep Tech®" for human and planetary health Fund V : $306 million (largest fund to date), announced April 2025 Annual Investment Pace : 60 pre-seed investments (~$550K each), 150 follow-on investments Decision Process and Investment Criteria Application Process : Submit online application (rolling basis, no fixed deadlines) Team reviews for fit (science quality, founder potential, market timing) Interview(s) if promising, potentially multiple rounds Term sheet offered to selected founders Timeline : Not publicly specified, but implied to be 4-8 weeks from application to decision Investment Committee : Appears to be partnership-based decision making with multiple GPs involved Warm Introductions : While not explicitly required, being introduced by current founders or investors likely accelerates process Notable Exits and Success Stories Acquisitions : Upside Foods (cultured meat) MycoWorks (bio-based leather, highly visible exits) BuildKite (CI/CD, acquired by Atlassian) NotCo (alternative proteins, highest-profile success) Active High-Growth Portfolio : Prellis Biologics (bioprinted lymph nodes for drug development) The EVERY Company (precision fermentation for food ingredients) Endless West (molecular spirits) OneSkin (skin aging reversal) Catalog Technologies (data storage via DNA) Vertical Oceans (urban aquaculture) Competitive Positioning IndieBio remains unique in the biotech accelerator landscape: Infrastructure Advantage : Proprietary wet labs with BSL-rated facilities Capital Depth : $1.5B parent fund provides multi-stage follow-on capacity Domain Expertise : Partnership includes scientific leaders from DARPA, ONR, Telefónica, publishing industry Track Record : 270+ companies, $12B+ value created since 2014 Founder-Friendly : High funding ($525K), low equity dilution, long-term engagement Diversity Focus : 42% female founders, intentional inclusive approach Investment Range and Economics Check Sizes and Economics : Initial: Up to $525,000 for full-time cohort participation Target ownership: ~10% at pre-seed (inferred from follow-on participation) Follow-on commitment: 97% participation in >$1M rounds Board representation: Partners remain active in portfolio oversight Current Batch Status SF Cohort 16 (2025): 8 companies in acceleration, actively funding NY Cohort 9 (2024): 9 companies, New York focus with new 25,000 sq ft facility Investor Showcase : Scheduled for March 11, 2026 (NY location) featuring Pre-Seed through Series A companies Founder Profile and Preferences Based on portfolio analysis and website messaging: Sweet Spot : Undergraduates, graduate students, postdocs with breakthrough science Welcome : First-time founders, international founders, career-switchers from academia/industry Diversity : Actively seeks underrepresented founders (42% female representation exceeds VC average) Stage Comfort : "Too early" is ideal (paper plans without data are acceptable) Background : Scientists, engineers, and technical founders preferred, business experience less critical Sector Mapping Portfolio distribution across sectors: Climate Tech : 70+ companies (largest bucket) Human Health : 79 companies Therapeutics : 42 companies Female Founders : 81 companies (cross-sector theme) Materials : 15 companies Energy : 13 companies Physical AI : 21 companies (emerging focus) Anti-Thesis Based on portfolio and messaging, IndieBio tends NOT to fund: Non-technical founders without science background Companies relying purely on software/algorithms without biological implementation Traditional pharma/biotech models without innovation Non-mission-driven ventures (profitability alone insufficient) Market Position Summary IndieBio has established itself as the definitive early-stage biotech accelerator globally, with: Unmatched physical infrastructure (wet labs) Strongest capital position for pre-seed synthetic biology Most consistent track record (11+ years, 270+ companies) Best founder economics (high initial check, long-term partnership) Explicit diversity and inclusion focus The firm is currently in growth mode with expanded New York presence, new facility (2025), and a record-sized parent fund (Fund V, $306M) supporting aggressive deployment in deep tech biotech.